Consensus document on controversial issues in the treatment of complicated skin and skin-structure infections

International Journal of Infectious Diseases

Volumn 14, Issue SUPPL. 4, 2010, Pages

  Pan, Angelo ^a   Cauda, Roberto ^b   Concia, Ercole ^c   Esposito, Silvano ^d   Sganga, Gabriele ^b   Stefani, Stefania ^e   Nicastri, Emanuele ^f,i   Lauria, Francesco N ^f,i   Carosi, Giampiero ^g,i   Moroni, Mauro ^h   Ippolito, Giuseppe ^f,i  

^a Divisione di Malattie Infettive   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e UNIVERSITY OF CATANIA   (Italy)

^f NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^g UNIVERSITY OF BRESCIA   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

ⁱ GISIG Gruppo Italiano di Studio sulle Infezioni Gravi Coordinating Committee   (Italy)

Author keywords

Antibiotic therapy; Complicated skin and skin structure infections; MRSA; Staphylococcus aureus; Topical negative therapy

Indexed keywords

AMIKACIN; AMINOPENICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAMASE INHIBITOR; CEFAZOLIN; CEFTAZIDIME; CEFTOBIPROLE; CIPROFLOXACIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GENTAMICIN; IMIPENEM; LINEZOLID; METICILLIN; METRONIDAZOLE; OXACILLIN; SULTAMICILLIN; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; CLINICAL PRACTICE; CONSENSUS DEVELOPMENT; DEBRIDEMENT; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; HOSPITAL INFECTION; HUMAN; ITALY; MEDIASTINITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; NONHUMAN; PRACTICE GUIDELINE; SKIN INFECTION; STERNOTOMY; SURGICAL INFECTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VACUUM ASSISTED CLOSURE; WOUND CARE; WOUND CLOSURE; WOUND DRESSING; WOUND INFECTION;

AGED; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; NEGATIVE-PRESSURE WOUND THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN DISEASES, BACTERIAL; STANDARD OF CARE; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS; SURGICAL WOUND INFECTION; TREATMENT OUTCOME;

EID: 78149358894     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2010.05.007     Document Type: Article

References (55)

1. Stevens D.L., Bisno A.L., Chambers H.F., Everett E.D., Dellinger P., Goldstein E.J., et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005, 41:1373-1406.
2. Stryjewski M.E., Chambers H.F. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008, 46(Suppl 5):S368-S377.
3. Wulf M., Voss A. MRSA in livestock animals-an epidemic waiting to happen?. Clin Microbiol Infect 2008, 14:519-521.
4. Pan A., Battisti A., Zoncada A., Bernieri F., Boldini M., Franco A., et al. Community-acquired methicillin-resistant Staphylococcus aureus ST398 infection. Italy. Emerg Infect Dis 2009, 15:845-847.
5. Smith J. Debridement of diabetic foot ulcers. Cochrane Database Syst Rev 2002, (4):CD003556.
6. Weigelt J., Itani K., Stevens D., Lau W., Dryden M., Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005, 49:2260-2266.
7. Stevens D.L., Herr D., Lampiris H., Hunt J.L., Batts D.H., Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002, 34:1481-1490.
8. Stryjewski M.E., Graham D.R., Wilson S.E., O'Riordan W., Young D., Lentnek A., et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms. Clin Infect Dis 2008, 46:1683-1693.
9. Noel G.J., Strauss R.S., Amsler K., Heep M., Pypstra R., Solomkin J.S. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by Gram-positive bacteria. Antimicrob Agents Chemother 2008, 52:37-44.
10. Arbeit R.D., Maki D., Tally F.P., Campanaro E., Eisenstein B.I. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004, 38:1673-1681.
11. Singer A.J., Dagum A.B. Current management of acute cutaneous wounds. N Engl J Med 2008, 359:1037-1046.
12. Diehr S., Hamp A., Jamieson B., Mendoza M. Clinical inquiries. Do topical antibiotics improve wound healing?. J Fam Pract 2007, 56:140-144.
13. Bradley M., Cullum N., Nelson E.A., Petticrew M., Sheldon T., Torgerson D. Systematic reviews of wound care management: (2). Dressings and topical agents used in the healing of chronic wounds. Health Technol Assess 1999, 3:1-35.
14. Dryburgh N., Smith F., Donaldson J., Mitchell M. Debridement for surgical wounds. Cochrane Database Syst Rev 2008, (3):CD006214.
15. Fleischmann W., Strecker W., Bombelli M., Kinzl L. [Vacuum sealing as treatment of soft tissue damage in open fractures]. Unfallchirurg 1993, 96:488-492.
16. Argenta L.C., Morykwas M.J. Vacuum-assisted closure: a new method for wound control and treatment: clinical experience. Ann Plast Surg 1997, 38:563-576.
17. Raja S.G., Berg G.A. Should vacuum-assisted closure therapy be routinely used for management of deep sternal wound infection after cardiac surgery?. Interact Cardiovasc Thorac Surg 2007, 6:523-527.
18. van Rijen M., Bonten M., Wenzel R., Kluytmans J. Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers. Cochrane Database Syst Rev 2008, (4):CD006216.
19. Mangram A.J., Horan T.C., Pearson M.L., Silver L.C., Jarvis W.R. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1999, 20:250-278.
20. Lauria F.N., De Carli G., Nicastri E. Resistant and multi-resistant Gram-positive severe infections: the GISIG working methodology. Int J Infect Dis 2010, 14S:S13-S17.
21. Berg H.F., Brands W.G., van Geldorp T.R., Kluytmans-VandenBergh F.Q., Kluytmans J.A. Comparison between closed drainage techniques for the treatment of postoperative mediastinitis. Ann Thorac Surg 2000, 70:924-929.
22. Fleck T.M., Koller R., Giovanoli P., Moidl R., Czerny M., Fleck M., et al. Primary or delayed closure for the treatment of poststernotomy wound infections?. Ann Plast Surg 2004, 52:310-314.
23. Fuchs U., Zittermann A., Stuettgen B., Groening A., Minami K., Koerfer R. Clinical outcome of patients with deep sternal wound infection managed by vacuum-assisted closure compared to conventional therapy with open packing: a retrospective analysis. Ann Thorac Surg 2005, 79:526-531.
24. Scholl L., Chang E., Reitz B., Chang J. Sternal osteomyelitis: use of vacuum-assisted closure device as an adjunct to definitive closure with sternectomy and muscle flap reconstruction. J Card Surg 2004, 19:453-461.
25. Simek M., Hajek R., Zalesk B., Molitor M., Lonsky V., Grulichova J., et al. Topical negative pressure versus conventional treatment of deep sternal wound infection in cardiac surgery. European Wound Management Association Journal 2008, 8:17-20.
26. Song D.H., Wu L.C., Lohman R.F., Gottlieb L.J., Franczyk M. Vacuum assisted closure for the treatment of sternal wounds: the bridge between debridement and definitive closure. Plast Reconstr Surg 2003, 111:92-97.
27. Catarino P.A., Chamberlain M.H., Wright N.C., Black E., Campbell K., Robson D., et al. High-pressure suction drainage via a polyurethane foam in the management of poststernotomy mediastinitis. Ann Thorac Surg 2000, 70:1891-1895.
28. Segers P., De Jong A.P., Kloek J.J., De Mol B.A. Poststernotomy mediastinitis: comparison of two treatment modalities. Interact Cardiovasc Thorac Surg 2005, 4:555-560.
29. Sjögren J., Nilsson J., Gustafsson R., Malmsjo M., Ingemansson R. The impact of vacuum-assisted closure on long-term survival after post-sternotomy mediastinitis. Ann Thorac Surg 2005, 80:1270-1275.
30. Colwell A.S., Donaldson M.C., Belkin M., Orgill D.P. Management of early groin vascular bypass graft infections with sartorius and rectus femoris flaps. Ann Plast Surg 2004, 52:49-53.
31. Noel G.J., Bush K., Bagchi P., Ianus J., Strauss R.S. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008, 46:647-655.
32. Cepeda J.A., Whitehouse T., Cooper B., Hails J., Jones K., Kwaku F., et al. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. J Antimicrob Chemother 2004, 53:345-355.
33. Kohno S., Yamaguchi K., Aikawa N., Sumiyama Y., Odagiri S., Aoki N., et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother 2007, 60:1361-1369.
34. Lin D.F., Zhang Y.Z., Wu J.F., Wang F., Zheng J.C., Miao J.Z., et al. Linezolid for the treatment of infections caused by Gram-positive pathogens in China. Int J Antimicrob Agents 2008, 32:241-249.
35. Lipsky B.A., Itani K., Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis 2004, 38:17-24.
36. Itani K.M., Weigelt J., Li J.Z., Duttagupta S. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2005, 26:442-448.
37. Sharpe J.N., Shively E.H., Polk H.C. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg 2005, 189:425-428.
38. Li Z., Willke R.J., Pinto L.A., et al. Comparison of length of hospital stay for patients with known or suspected methicilliresistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multi center trial. Pharmacotherapy 2001, 21:263-274.
39. Wilcox M., Nathwani D., Dryden M. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. J Antimicrob Chemother 2004, 53:335-344.
40. Nichols R.L., Graham D.R., Barriere S.L., Rodgers A., Wilson S.E., Zervos M., et al. Treatment of hospitalized patients with complicated Gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. J Antimicrob Chemother 1999, 44:263-273.
41. Breedt J., Teras J., Gardovskis J., Maritz F.J., Vaasna T., Ross D.P., et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005, 49:4658-4666.
42. Ellis-Grosse E.J., Babinchak T., Dartois N., Rose G., Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005, 41(Suppl 5):S341-S353.
43. Florescu I., Beuran M., Dimov R., Razbadauskas A., Bochan M., Fichev G., et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 2008, 62(Suppl 1):i17-28.
44. Sacchidanand S., Penn R.L., Embil J.M., Campos M.E., Curcio D., Ellis Grosse E., et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005, 9:251-261.
45. Talbot G.H., Thye D., Das A., Ge Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007, 51:3612-3616.
46. Jauregui L.E., Babazadeh S., Seltzer E., Goldberg L., Krievins D., Frederick M., et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005, 41:1407-1415.
47. Seltzer E., Dorr M.B., Goldstein B.P., Perry M., Dowell J.A., Henkel T. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 2003, 37:1298-1303.
48. Stryjewski M.E., O'Riordan W.D., Lau W.K., Pien F.D., Dunbar L.M., Vallee M., et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to Gram-positive bacteria. Clin Infect Dis 2005, 40:1601-1607.
49. Stryjewski M.E., Chu V.H., O'Riordan W.D., Warren B.L., Dunbar L.M., Young D.M., et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by Gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006, 50:862-867.
50. Van der Auwera P., Aoun M., Meunier F. Randomized study of vancomycin versus teicoplanin for the treatment of Gram-positive bacterial infections in immunocompromised hosts. Antimicrob Agents Chemother 1991, 35:451-457.
51. Wilcox M.H., Tack K.J., Bouza E., Herr D.L., Ruf B.R., Ijzerman M.M., et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis 2009, 48:203-212.
52. Stevens D.L., Smith L.G., Bruss J.B., McConnell-Martin M.A., Duvall S.E., Todd W.M., et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000, 44:3408-3413.
53. Giordano P., Song J., Pertel P., Herrington J., Kowalsky S. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. Int J Antimicrob Agents 2005, 26:357-365.
54. Sjogren J., Malmsjo M., Gustafsson R., Ingemansson R. Poststernotomy mediastinitis: a review of conventional surgical treatments, vacuum-assisted closure therapy and presentation of the Lund University Hospital mediastinitis algorithm. Eur J Cardiothorac Surg 2006, 30:898-905.
55. Gregor S., Maegele M., Sauerland S., Krhan J.F., Peinemaa F., Lange S. Negative pressure wound therapy: a vacuum of evidence?. Arch Surg 2008, 143:189-196.